|
|
Pro-LNG-S |
|
Vaxjo ID |
188 |
|
Vaccine Adjuvant Name |
Pro-LNG-S |
|
Adjuvant VO ID |
VO_0005472
|
|
Description |
cholesterol capped toll-like receptor 7/8 agonist that induces a Th1 response and CD8 T cells |
|
Stage of Development |
Research |
|
Location Licensed |
South Korea (Progeneer) |
|
Host Species for Testing |
3 |
|
Components |
cholesterol/ liposome formulation |
|
Storage |
2-8C |
|
Preparation |
shown in Supplementary Figs. 1–3 of linked publication in reference |
| References |
(Kang, 2024): Vaccine Adjuvant Compendium - VAC [https://vac.niaid.nih.gov/view?id=34]
Jin et al., 2023: Jin SM, Yoo YJ, Shin HS, Kim S, Lee SN, Lee CH, Kim H, Kim JE, Bae YS, Hong J, Noh YW, Lim YT. A nanoadjuvant that dynamically coordinates innate immune stimuli activation enhances cancer immunotherapy and reduces immune cell exhaustion. Nature nanotechnology. 2023; 18(4); 390-402. [PubMed: 36635335].
|
|
